Compare ERC & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | NTHI |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.5M | 243.9M |
| IPO Year | N/A | N/A |
| Metric | ERC | NTHI |
|---|---|---|
| Price | $9.01 | $9.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.2K | 29.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.65 | $3.20 |
| 52 Week High | $9.78 | $16.00 |
| Indicator | ERC | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 20.91 | 46.99 |
| Support Level | N/A | $8.29 |
| Resistance Level | $9.45 | $10.52 |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 8.51 | 20.28 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).